- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05259709
Um estudo de imagem ImmunoPet usando 89Zr-DFO-REGN5054 em participantes adultos com cânceres sólidos tratados com Cemiplimabe
Um primeiro estudo em humanos da tomografia por emissão de pósitrons 89Zr-DFO-REGN5054 (Anti-CD8) em pacientes com neoplasias sólidas tratados com Cemiplimabe
This study is researching an experimental drug called 89Zr-DFO-REGN5054 and cemiplimab. The study is focused on patients with a type of cancer that can be potentially imaged using 89Zr-DFO-REGN5054 and show special tumor features that may be important to the way the immune system fights cancer.
The aim of the study is to study the safety and tolerability (how the body reacts to the drug) of the imaging agent 89Zr-DFO REGN5054.
The study is looking at several other research questions, including:
- What side effects may happen from taking the study drugs
- How much study drug is in the blood at different times
- Whether the body makes antibodies against the study drugs (which could make the study drugs less effective or could lead to side effects)
Visão geral do estudo
Status
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
-
Groningen, Holanda, 9700 RB
- UMC Groningen
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Key Inclusion Criteria:
- Advanced or metastatic solid tumors that may respond to anti-programmed cell death 1 (PD-1) immunotherapy
- Measurable disease according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 criteria
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤1
- Adequate organ and bone marrow function as defined in the protocol
- Willing and able to comply with clinic visits and study-related procedures (including required tumor biopsy for Part B)
Key Exclusion Criteria:
- Currently receiving another cancer treatment or inadequate time since last therapy, as defined in the protocol
- Has not yet recovered from acute toxicities from prior therapy; exceptions defined in the protocol
- Prior treatment with a blocker of the PD-1/Programmed death ligand 1 (PD-L1) pathway
- Currently receiving or has received chimeric antigen receptor (CAR-T) cell therapy
- Symptomatic or untreated brain metastases, leptomeningeal disease, or spinal cord compression
- Known history of or any evidence of interstitial lung disease, active, noninfectious pneumonitis (past 5 years) or active tuberculosis
NOTE: Other protocol defined inclusion/exclusion criteria apply.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição sequencial
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Single ascending dose of 89Zr˗DFO˗REGN5054 followed by fixed dose of cemiplimab
Part A: Doses of 89Zr˗DFO˗REGN5054 may be reduced based upon assessment. |
Administered by intravenous (IV) infusion during Part A and B. Administered by IV infusion every 3 weeks (Q3W).
Outros nomes:
|
|
Experimental: Defined dose of 89Zr˗DFO˗REGN5054 followed by fixed dose of cemiplimab
Part B: Defined dose of 89Zr˗DFO˗REGN5054 determined in Part A. |
Administered by intravenous (IV) infusion during Part A and B. Administered by IV infusion every 3 weeks (Q3W).
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Incidence and severity of treatment-emergent adverse events (TEAEs)
Prazo: Up to day 8, after the infusion of 89Zr˗DFO˗REGN5054
|
Part A |
Up to day 8, after the infusion of 89Zr˗DFO˗REGN5054
|
|
Incidence and severity of TEAEs
Prazo: Up to approximately week 115
|
Part A and B |
Up to approximately week 115
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Clinical dosimetry based on tissue radiation absorbed dose calculated from positron emission tomography (PET) image acquisition data
Prazo: On days 1, 5 and 8
|
After injection of 37 megabecquerel (MBq) of 89Zr-DFO-REGN5054, a series of whole-body positron emission tomography (PET) images will be obtained over a period of up to 8 days and corrected for attenuation by low-dose computed tomography (CT) scans using PET/CT. The radiation effective dose per organ/tissue will be calculated for each organ using Organ Level INternal Dose Assessment/EXponential Modeling (OLINDA/EXM). The unit of effective dose per organ/tissue will be millisievert per Minimum Base Quantity (MBq) for each participant's organ/tissue. The final values for each organ will be averaged across participants for each mass dose |
On days 1, 5 and 8
|
|
Clinical dosimetry based on tissue radiation effective dose calculated from PET image acquisition data
Prazo: On days 1, 5 and 8
|
After injection of 37 MBq of 89Zr-DFO-REGN5054, a series of whole-body PET images will be obtained over a period of up to 8 days and corrected for attenuation by low-dose CT scans using PET/CT. The radiation effective dose for the whole body will be calculated using OLINDA/EXM software. The unit of effective dose will be millisievert per MBq for the whole body for each participant. The final values will be averaged across participants for each mass dose. |
On days 1, 5 and 8
|
|
Concentration of 89Zr-DFO-REGN5054 in serum
Prazo: On days 1, 5 and 8
|
Part A |
On days 1, 5 and 8
|
|
Serum imaging agent activity concentration of area under the curve (AUC0-7)
Prazo: Up to day 8
|
Part A |
Up to day 8
|
|
89Zr-DFO-REGN5054 uptake across cluster of differentiation 8 (CD8)-expressing normal tissues and tumors
Prazo: At the time of imaging, up to day 8
|
Part A and Part B |
At the time of imaging, up to day 8
|
|
Blood pool uptake of 89Zr-DFO-REGN5054 with subsequent calculation of standardized uptake value (SUV) tumor-to-blood ratios
Prazo: At the time of imaging, up to day 8
|
Part A and Part B |
At the time of imaging, up to day 8
|
|
Association of 89Zr˗DFO˗REGN5054 autoradiographic signal intensity distribution with CD8 expression in tumor tissues
Prazo: At Baseline
|
Part A and Part B |
At Baseline
|
|
Association of 89Zr-DFO-REGN5054 uptake with CD8 expression in tumor tissues
Prazo: At Baseline
|
Part B |
At Baseline
|
|
Association of tumor-to-blood ratio of 89Zr-DFO-REGN5054 with CD8 expression in tumor tissues
Prazo: At Baseline
|
Part B |
At Baseline
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Clinical Trials Management, Regeneron Pharmaceuticals
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- R5054-ONC-1843
- 2019-001604-38 (Número EudraCT)
- 2019 (Concessão/Contrato do NIH dos EUA)
- 2024-515351-37-00 (Ctis)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Prazo de Compartilhamento de IPD
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
Critérios de acesso de compartilhamento IPD
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
- CIF
- ANALYTIC_CODE
- CSR
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .